HuGE Literature Finder
Records 1-7
Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.
Cancer medicine 2019 Dec . Grenda Anna, Blach Justyna, Szczyrek Michal, Krawczyk Pawel, Nicos Marcin, Kuznar Kaminska Barbara, Jakimiec Monika, Balicka Grazyna, Chmielewska Izabela, Batura-Gabryel Halina, Sawicki Marek, Milanowski Janu |
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
The New England journal of medicine 2016 Jun 374 (26): 2530-41. Gotlib Jason, Kluin-Nelemans Hanneke C, George Tracy I, Akin Cem, Sotlar Karl, Hermine Olivier, Awan Farrukh T, Hexner Elizabeth, Mauro Michael J, Sternberg David W, Villeneuve Matthieu, Huntsman Labed Alice, Stanek Eric J, Hartmann Karin, Horny Hans-Peter, Valent Peter, Reiter Andre |
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study.
Journal of cancer research and clinical oncology 2015 Nov 141 (11): 2047-60. Hochhaus Andreas, Baccarani Michele, Giles Francis J, le Coutre Philipp D, Müller Martin C, Reiter Andreas, Santanastasio Helene, Leung Mimi, Novick Steven, Kantarjian Hagop |
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
PloS one 2014 9 (1): e85362. Damaj Gandhi, Joris Magalie, Chandesris Olivia, Hanssens Katia, Soucie Erinn, Canioni Danielle, Kolb Brigitte, Durieu Isabelle, Gyan Emanuel, Livideanu Cristina, Chèze Stephane, Diouf Momar, Garidi Reda, Georgin-Lavialle Sophie, Asnafi Vahid, Lhermitte Ludovic, Lavigne Christian, Launay David, Arock Michel, Lortholary Olivier, Dubreuil Patrice, Hermine Olivi |
The frequencies of human neutrophil alloantigens among the Japanese population.
Tissue antigens 2012 Jul 9999 (9999): 9999. Matsuhashi M, Tsuno NH, Kawabata M, Mishima Y, Okochi N, Santoso S, Tozuka M, Takahashi K |
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
Investigational new drugs 2012 Apr 30 (2): 819-27. Yoon Dok Hyun, Ryu Min-Hee, Ryoo Baek-Yeol, Beck Moyeol, Choi Dae Ro, Cho Yoojin, Lee Jae-Lyun, Chang Heung-Moon, Kim Tae Won, Kang Yoon-K |
A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor.
Oncology 2009 Mar 76 (5): 5. Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 19, 2021
- Content source: